

Aimmune Therapeutics, Inc.  
Form 8-K  
January 02, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 27, 2018**

**AIMMUNE THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**001-37519**  
**(Commission**

**File Number)**  
**8000 Marina Blvd, Suite 300**

**45-2748244**  
**(IRS Employer**

**Identification Number)**

Edgar Filing: Aimmune Therapeutics, Inc. - Form 8-K

**Brisbane, CA 94005**

**(Address of principal executive offices, including Zip Code)**

**Registrant's telephone number, including area code: (650) 614-5220**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On December 27, 2018, Aimmune Therapeutics, Inc. (the Company) entered into a letter agreement with Stephen Dilly, M.B.B.S., Ph.D. that extends the date his employment as a special advisor to the Company will end to December 31, 2019. Under the letter agreement, Dr. Dilly is scheduled to work not less than 2 ½ days per week, will be paid at the rate of \$12,000 per year and will no longer be eligible for additional per diem compensation. Dr. Dilly's outstanding equity awards will continue to vest for as long as he serves the Company as special advisor.

The foregoing summary of the material terms of the letter agreement entered into with Dr. Dilly is qualified in its entirety by the full text of letter agreement. The letter agreement will be filed as an exhibit in the Annual Report for the period ended December 31, 2018.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AIMMUNE THERAPEUTICS, INC.**

Date: January 2, 2019

By: /s/ Douglas T. Sheehy  
Douglas T. Sheehy  
General Counsel and Secretary